Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme.
Streptococcal inhibitor of complement (SIC) is a 31-kDa extracellular protein of a few, very virulent, strains of Streptococcus pyogenes (particularly M1 strains). It is secreted in large quantities (about 5 mg/liter) and inhibits complement lysis by blocking the membrane insertion site on C5b67. We describe investigations into the interaction of SIC with three further major components of the innate immune system found in airway surface liquid, namely, secretory leukocyte proteinase inhibitor (SLPI), lysozyme, and lactoferrin. Enzyme-linked immunosorbent assays showed that SIC binds to SLPI and to both human and hen egg lysozyme (HEL) but not to lactoferrin. Studies using (125)I-labeled proteins showed that SIC binds approximately two molecules of SLPI and four molecules of lysozyme. SLPI binding shows little temperature dependence and a small positive enthalpy, suggesting that the binding is largely hydrophobic. By contrast, lysozyme binding shows strong temperature dependence and a substantial negative enthalpy, suggesting that the binding is largely ionic. Lysozyme is precipitated from solution by SIC. Further studies examined the ability of SIC to block the biological activities of SLPI and lysozyme. An M1 strain of group A streptococci was killed by SLPI, and the antibacterial activity of this protein was inhibited by SIC. SIC did not inhibit the antiproteinase activity of SLPI, implying that there is specific inhibition of the antibacterial domain. The antibacterial and enzymatic activities of lysozyme were also inhibited by SIC. SIC is the first biological inhibitor of the antibacterial action of SLPI to be described and may prove to be an important tool for investigating this activity in vivo. Inhibition of the antibacterial actions of SLPI and lysozyme would be advantageous to S. pyogenes in establishing colonization on mucosal surfaces, and we propose that this is the principal function of SIC.
Fernie-King
Barbara A
BA
Microbial Immunology Group, Centre for Veterinary Science, University of Cambridge, Cambridge, United Kingdom. baf22@cam.ac.uk
Seilly
David J
DJ
Davies
Alexandra
A
Lachmann
Peter J
PJ
D000818:Animals; D001426:Bacterial Proteins / Q000302:isolation & purification / Q000378:metabolism / Q000633:toxicity; D002645:Chickens; D003169:Complement Inactivator Proteins / Q000302:isolation & purification / Q000378:metabolism / Q000633:toxicity*; D004791:Enzyme Inhibitors / Q000302:isolation & purification / Q000378:metabolism / Q000633:toxicity; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D018928:Immunity, Mucosal / Q000187:drug effects*; D066298:In Vitro Techniques; D007781:Lactoferrin / Q000187:drug effects / Q000378:metabolism; D009113:Muramidase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011485:Protein Binding; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D053481:Secretory Leukocyte Peptidase Inhibitor; D013297:Streptococcus pyogenes / Q000187:drug effects / Q000472:pathogenicity*; D013816:Thermodynamics
D001426:Bacterial Proteins; D003169:Complement Inactivator Proteins; D004791:Enzyme Inhibitors; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; D011994:Recombinant Proteins; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D009113:Muramidase; D007781:Lactoferrin